Differing perspectives among gastric motility experts and regulatory roadblocks impede clinical care, but some companies are ...

Gastrointestinal (GI) disorders—including IBS, IBD, GERD, peptic ulcers, and constipation—affect a large portion of the global population and impose significant healthcare burdens. Conventional ...

Too much rendang? Rich holiday meals and overindulgence - as well as lying down too soon after eating - can lead to ...

Dr. Mike and Trisha Pasricha, MD, breakdown bathroom habits ...

() has held its Q4 earnings call. Read on for the main highlights of the call. Claim 70% Off TipRanks Premium. Unlock hedge fund-level data and powerful investing t ...

Dyspepsia affects an estimated 15 to 25 per cent of Malaysians, making it one of the most common gastrointestinal complaints ...

Conference call will be held today, Thursday, March 19 at 9:00 am ETCARMEL, Ind., March 19, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical ...

NeurAxis, Inc. (AMEX:NRXS) Q4 2025 Earnings Call Transcript March 19, 2026 Operator: Ladies and gentlemen, thank you for ...

A 230-basis-point gross margin decline in 2025 was attributed to higher discounting in financial assistance programs and ...

Background and rationaleIrritable bowel syndrome (IBS), a core disorder of gut–brain interaction, remains one of the most common and heterogeneous ...

NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of IB-Stim® , which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) ...

NeurAxis, Inc. (NYSE: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the ...